Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067464 | 0.80 | PTPN2 (0.58) | PTPN1SMN1; SMN2LMNAKDM4EADORA2A | |
| SCHEMBL8090363 | 0.79 | MAPT (0.43) | ALDH1A1HPGDRAB9ANPC1MAPT | |
| SCHEMBL5063495 | 0.78 | KMT2A (0.64) | SMN1; SMN2ALDH1A1KDM4ETDP1RAB9A | |
| SCHEMBL5049650 | 0.77 | PKM (0.45) | SMN1; SMN2KDM4EHPGDRAB9ANPC1 | |
| SCHEMBL6857304 | 0.77 | PTPN2 (0.48) | SMN1; SMN2KDM4EHPGDRAB9ANPC1 | |
| SCHEMBL11820171 | 0.76 | GSK3B (0.46) | SMN1; SMN2ALDH1A1LMNANPSR1HPGD | |
| SCHEMBL12213152 | 0.76 | PTK2 (0.59) | SMN1; SMN2ALDH1A1HPGDTDP1RAB9A | |
| SCHEMBL29515001 | 0.74 | ALDH1A1 (0.55) | PTPN1SMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL765316 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL11777129 | 0.74 | GSK3B (0.43) | SMN1; SMN2HPGDRAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080102068-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080102068-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | PTPN1 3834/4885SMN1; SMN2 1919/4885ALDH1A1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.